PharmaCyte Biotech to Present Pancreatic Cancer Therapy at 2017 BIO International Convention
June 13 2017 - 9:20AM
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage
biotechnology company focused on developing cellular therapies for
cancer and diabetes using its signature live-cell encapsulation
technology, Cell-in-a-Box®, today announced that its Chief
Executive Officer, Kenneth L. Waggoner, will present PharmaCyte’s
therapy for pancreatic cancer at the 2017 BIO International
Convention (BIO). BIO is to be held June 17-22, 2017 in San Diego,
California at the San Diego Convention Center. This year’s theme is
“Breakthrough,” which is designed to highlight the breakthrough
leadership, technology and science that happens every day in the
biotechnology industry.
PharmaCyte’s Chief Executive Officer, Kenneth L.
Waggoner, commented, “We are again excited to attend this year’s
BIO after just completing a working session with leading clinical
oncologists at the ASCO annual meeting where we updated them on
efforts to begin our clinical trial in locally advanced pancreatic
cancer (LAPC).
“Having won the 2017 Buzz of BIO 'Pipelines of
Promise' award, we have been given the opportunity to build
upon that by presenting PharmaCyte’s therapy for pancreatic cancer
to thousands of industry leaders who will attend this year’s
convention.
“We are also being interviewed by Mike Huckman,
a former pharmaceuticals reporter for CNBC, to showcase our
pancreatic cancer therapy. And we have meetings scheduled with
potential strategic partners, biotech companies that have expressed
an interest in PharmaCyte and numerous other industry thought
leaders who have reached out to us to learn more about
PharmaCyte.”
BIO is the world’s largest biotechnology convention. It attracts
over 16,000 biotechnology and pharma leaders who come together for
one week of intensive networking to discover new opportunities and
promising partnerships. BIO brings together a wide spectrum of life
science and application areas, including drug discovery,
biomanufacturing, genomics, biofuels, nanotechnology and cell
therapy. There will be more than 40,000 BIO “One-on-One Partnering”
meetings, approximately 1,800 exhibitors (including 50 State and
International pavilions), 150 educational sessions and 300 company
presentations – a record breaking number for BIO.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage
biotechnology company developing cellular therapies for cancer and
diabetes based upon a proprietary cellulose-based live cell
encapsulation technology known as “Cell-in-a-Box®.” This technology
will be used as a platform upon which therapies for several types
of cancer and diabetes are being developed.
PharmaCyte’s therapy for cancer involves
encapsulating genetically engineered human cells that convert an
inactive chemotherapy drug into its active or “cancer-killing”
form. These encapsulated cells are implanted as close to the
patient’s cancerous tumor as possible. Once implanted, a
chemotherapy drug that is normally activated in the liver
(ifosfamide) is given intravenously at one-third the normal dose.
The ifosfamide is carried by the circulatory system to where the
encapsulated cells have been implanted. When the ifosfamide flows
through the encapsulated cells, they act as a “bio-artificial
liver” and activate the chemotherapy drug at the site of the
cancer. This “targeted chemotherapy” has proven effective and safe
to use in past clinical trials and results in no treatment related
side effects.
PharmaCyte’s therapy for Type 1 diabetes and
insulin-dependent Type 2 diabetes involves encapsulating a human
cell line that has been genetically engineered to produce, store
and release insulin in response to the levels of blood sugar in the
human body. The encapsulation will be done using the Cell-in-a-Box®
technology. Once the encapsulated cells are implanted in a diabetic
patient, they will function as a “bio-artificial pancreas” for
purposes of insulin production.
Safe Harbor
This press release contains forward-looking
statements, which are generally statements that are not historical
facts. Forward-looking statements can be identified by the words
"expects," "anticipates," "believes," "intends," "estimates,"
"plans," "will," "outlook" and similar expressions. Forward-looking
statements are based on management's current plans, estimates,
assumptions and projections, and speak only as of the date they are
made. We undertake no obligation to update any forward-looking
statement because of new information or future events, except as
otherwise required by law. Forward-looking statements involve
inherent risks and uncertainties, most of which are difficult to
predict and are generally beyond our control. Actual results or
outcomes may differ materially from those implied by the
forward-looking statements due to the impact of numerous risk
factors, many of which are discussed in more detail in our Annual
Report on Form 10-K and our other reports filed with the Securities
and Exchange Commission.
More information about PharmaCyte Biotech can be
found at www.PharmaCyte.com. Information may also be obtained by
contacting PharmaCyte’s Investor Relations Department.
Contact:
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com